4DMedical Ltd (ASX: 4DX) is once again one of the standout performers on the ASX.
On Friday afternoon, the ASX healthcare share was up 11% to $4.29, defying a weak broader market that saw the S&P/ASX 200 Index (ASX: XJO) fall around 1%.
The longer-term performance is even more remarkable. Over the past 12 months, 4DMedical shares have soared approximately 1,616%, leaving the benchmark index’s 3.3% gain in the dust.
So, what keeps driving this ASX healthcare stock higher?
Image source: Getty Images
No fresh news, plenty of momentum
Interestingly, there doesn’t appear to be any new ASX announcement today that would fully explain the latest jump in the ASX healthcare share.
Instead, investors seem to be continuing to respond to a string of major developments announced in recent weeks, as well as growing confidence in the company’s long-term commercial opportunity.
4DMedical develops advanced respiratory imaging technology that enables clinicians to assess lung function in ways traditional imaging methods cannot. Its flagship products use proprietary software and artificial intelligence to generate detailed functional images of the lungs, providing valuable insights for diagnosis and treatment.
As healthcare systems increasingly embrace AI-powered diagnostic tools, investors appear to be betting that 4DMedical is well-positioned to benefit.
Expanding globally
One of the company’s most significant recent moves was its acquisition of Austrian AI imaging company Contextflow.
The deal gives the $2.5 billion ASX healthcare share an immediate commercial foothold in Europe, access to lung cancer screening technology, and established reimbursement contracts in Germany.
Management estimates that the acquisition will expand its addressable market by approximately 50%, significantly increasing the company’s growth runway.
The transaction also strengthens 4DMedical’s position at the intersection of medical imaging and artificial intelligence, two sectors attracting substantial investor attention.
Entering a multi-billion dollar US market
Investors have also welcomed the company’s progress in the lucrative US healthcare market.
Recently, the ASX healthcare share announced a major commercial agreement with SimonMed, one of the largest outpatient medical imaging providers in the US, operating more than 170 imaging sites.
The partnership represents another important step in the rollout of the company’s CT:VQ lung imaging technology and provides access to a large network of potential patients and healthcare providers.
Earlier this month, the company also launched its CLEAR clinical program targeting acute pulmonary embolism.
Management believes this initiative could expand the US addressable market for CT:VQ to around US$3 billion, highlighting the scale of the opportunity ahead if adoption continues to grow.
What are the risks?
Despite the excitement, investors should remember that 4DMedical remains a high-growth healthcare company.
The valuation of the ASX 200 healthcare share has risen sharply, and expectations are now significantly higher than they were a year ago. Commercial adoption, reimbursement outcomes, and execution will all be critical to justifying the stock’s meteoric rise.
To keep the momentum going, management will need to continue converting clinical success into revenue growth, expand adoption of its technology across healthcare networks, and successfully integrate its European expansion strategy.
If it can deliver on those objectives, investors may believe the company’s remarkable run still has further to go.